Featured
Is Ozempic finally helping or still just hurting ResMed?
Is ResMed putting two-bob each way on the so-called 'Ozempic-effect'?
Markets
Two stocks the market gave up on just had their month
Health care was the best performing sector on the ASX 200 in August, and the two names that dragged it down for years did most…
Markets
Australia’s government now has $1 trillion in debt: four charts on how we got here and its cost
How did we get here? And what does it cost us in growing interest bills?
Markets
From $2.65 at IPO to cents on the dollar: why Saluda Medical’s next results are worth watching
Saluda Medical raised about $231 million at $2.65 in December, the biggest ASX float of the month. It now trades at 61 cents.
Markets
How to get into the copper trade on the ASX
Copper delivered more than half of BHP's earnings for the first time, and the ASX has almost no pure copper producers left to buy. Except…
Markets
CSL’s next CEO is coming: here’s what’s at stake
One fund manager told us the next CSL CEO is about a month away. Here's what's at stake when the name lands.
Markets
Is Treasury Wine Estates finally turning the corner?
Treasury Wine Estates reported a statutory loss over $1 billion, paid no dividend, yet beat its own earnings guidance all in the same result. On...
Markets
Life360 crossed 100 million users, but the market sold it off: CEO tells us why
Life360 crossed 100 million users and posted record revenue, and the market answered with a double-digit single-day fall in the share price. On this week's…
Markets
How blue-collar companies are using AI
Every article that focuses on how AI is impacting the modern workforce centres around white-collar workers. We asked Ryan Stokes, SGH CEO - whose companies…
Markets
CEO Ryan Stokes explains why SGH gave up its BlueScope chase
Rejection is tough, especially in big business. On this week's Switzer Show, SGH CEO, Ryan Stokes, explains he's done chasing Bluescope Steel as an acquisition…